Today: 22 March 2026
Subscribe
Browse Category

NASDAQ:SHPH 21 November 2025

Shuttle Pharmaceuticals (SHPH) Stock Soars on S‑1 Filing, Fresh Financing and AI Pivot – What Today’s Volatile Rally Means for Investors (21 Nov 2025)

Shuttle Pharmaceuticals (SHPH) Stock Soars on S‑1 Filing, Fresh Financing and AI Pivot – What Today’s Volatile Rally Means for Investors (21 Nov 2025)

Shuttle Pharmaceuticals (NASDAQ: SHPH) jumped over 25% in after-hours and pre-market trading on November 21, 2025, after filing a new S-1 registration statement. The filing registers 625,156 shares tied to a pre-funded warrant held by Alternative Investment Capital Inc., which could control about 47% of shares post-offering. Shuttle will not receive new proceeds, as cash was raised in a prior $2.5 million private placement.
21 November 2025
···

Stock Market Today

  • Pro Medicus (ASX:PME) Valuation Faces Mixed Signals After Leadership Changes
    March 22, 2026, 12:50 AM EDT. Pro Medicus (ASX:PME) has restructured its senior leadership, appointing Danny English as CFO and moving Clayton Hatch to combined operational roles. The stock trades at A$120.06, down 2.09% in one day and 46.07% year-to-date, despite a strong 5-year total return of 173.62%. Analysts suggest the company is 39% undervalued with a fair value at A$196.78, citing steady revenue growth and expanding market potential. However, its high price-to-earnings (P/E) ratio of 53.4x exceeds peers and fair estimates, posing a valuation risk if growth expectations are not met. Key risks include accelerated AI adoption in imaging and contract delays with U.S. hospitals. Investors face a split market sentiment on PME's true value amid recent leadership changes and performance concerns.
Go toTop